Zobrazeno 91 - 100
of 47 833
pro vyhledávání: ''
Publikováno v:
Biochemical and Biophysical Research Communications. 567:79-85
circRNAs have been suggested to modulate NSCLC tumorigenesis and drug resistance. Whether circSNX6 affects NSCLC remains unclear. In this study, we aim to investigate the role of circSNX6 in drug resistance of NSCLC exposed to cisplatin. RT-qPCR meth
Autor:
Teresa Cristina Cardoso Fonseca, Patrizia Larghero, Regiana Quinto de Souza, Lisandro Ribeiro, Carmen Bonfim, Francianne Gomes Andrade, Ingrid Sardou-Cezar, Teresa de Souza Fernandez, Bruno Almeida Lopes, Maria S. Pombo-de-Oliveira, Gisele Loth, Rolf Marschalek, Claus Meyer, Elissa Santos Morgado
Publikováno v:
Cancer Genetics. :86-90
Therapy-related acute myeloid leukemia (t-AML) following treatment with topoisomerase-II inhibitors has been increasingly reported. These compounds (e.g. etoposide) promote DNA damage and are associated with KMT2A rearrangements. They are widely used
Publikováno v:
Seminars in Cancer Biology. 73:101-115
Selective estrogen receptor modulators (SERMs) are a class of compounds that bind to estrogen receptors (ERs) and possess estrogen agonist or antagonist actions in different tissues. As such, they are widely used drugs. For instance, tamoxifen, the m
Autor:
Veronica Conca, Matteo Clavarezza, Chiara Cremolini, Alessandra Boccaccino, Filippo Pietrantonio, Roberto Moretto, Cristina Granetto, Gianluca Tomasello, Alessandro Bertolini, Antonio Frassoldati, Alfredo Falcone, Mirella Giordano, Alessandro Passardi, Sara Lonardi, Anello Marcello Poma, Gianluca Masi, Gabriella Fontanini, Clara Ugolini, Giuseppe Aprile, Marco Maria Germani
Publikováno v:
European Journal of Cancer. 153:16-26
Background Recent data from the TRIBE2 study have failed to suggest a higher magnitude of benefit from upfront FOLFOXIRI/bevacizumab in patients with BRAF-mutant metastatic colorectal cancer (mCRC) as previously reported in the TRIBE study. Patients
Autor:
Andrew Plumb, Mike Hubank, Katrina M. Ingley, Debbie Hughes, Sandra J. Strauss, Louis Chesler, Rachel Cox, Daniel Lindsay
Publikováno v:
Lung Cancer. 158:151-155
Here, we present the case of an adolescent with a rare metastatic Inflammatory myofibroblastic tumor (IMT) harboring a TFG-ROS1 fusion initially detected on tumor progression and retrospectively identified in the primary tumor after targeted RNA sequ
Publikováno v:
Future Medicinal Chemistry. 13:1253-1269
Background: STAT3 is a pro-oncogenic transcription factor. Pyrimethamine (PYM) is a STAT3 inhibitor that suppresses the proliferation of some cancer cells through downregulation of STAT3 target proteins. Methodology & Results: We have used structure-
Publikováno v:
DNA and Cell Biology. 40:1101-1111
Chronic myeloid leukemia (CML) is characterized by the formation of the BCR-ABL fusion gene. The BCR-ABL protein leads to an increased level of reactive oxygen species, which is a major cause of endogenous DNA double-strand breaks (DSBs). CML cells a
Autor:
Stephen V. Liu
Publikováno v:
Lung Cancer. 158:25-28
NRG1 fusions are rare oncogenic drivers that exist at low frequencies across multiple tumor types. They are uncommon in lung cancer with an estimated incidence of 0.2 %. NRG1 fusions have a unique biology and are challenging to detect, due to large i
Autor:
Rui Li, Limei Yin, Sun Chuntang, Kemin Li, Jianxin Xue, Ruizhan Tong, Rutie Yin, Zhipeng Zhou, Y. Liu, You Lu, Pansong Li
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 110:1432-1441
Purpose This work assessed local and systemic alternations of the tumor immune microenvironment during concurrent chemoradiation therapy (CCRT) of local advanced cervical cancer to estimate the optimal timing for immune therapy in relation to CCRT. M
Autor:
Clémence Breton, Jean-Baptiste Bachet, Jaafar Bennouna, Sylvain Manfredi, Jean-Louis Legoux, Aimery de Gramont, Karine Le Malicot, Thomas Aparicio, Thierry Lecomte, Olivier Bouché, Michel Ducreux, Olayidé Boussari, Julien Taieb, Jean-Marc Gornet
Publikováno v:
European Journal of Cancer. 153:40-50
Few studies have explored the association between baseline characteristics and the occurrence of early toxicities in patients treated with first-line chemotherapy for metastatic colorectal cancer (mCRC).Individual patient data of 2190 patients enroll